To investigate the value of circulating DNA when combined with other blood-based biomarkers, another study evaluated the power of combined detection of circulating cfDNA, AFP, and α l-fucosidase (AFU) for diagnosis of HCC in serum samples from 39 HCC patients and 45 normal controls. This evidence concerns the gene AFP and hepatocellular carcinoma.